# SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

> **NCT00006003** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** semaxanib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00006003
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-07
- **Primary completion:** 2003-07
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006003, "SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00006003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*